JP2009504591A5 - - Google Patents

Download PDF

Info

Publication number
JP2009504591A5
JP2009504591A5 JP2008525474A JP2008525474A JP2009504591A5 JP 2009504591 A5 JP2009504591 A5 JP 2009504591A5 JP 2008525474 A JP2008525474 A JP 2008525474A JP 2008525474 A JP2008525474 A JP 2008525474A JP 2009504591 A5 JP2009504591 A5 JP 2009504591A5
Authority
JP
Japan
Prior art keywords
heteroaryl
formula
pharmaceutically acceptable
acceptable salt
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008525474A
Other languages
English (en)
Japanese (ja)
Other versions
JP5112316B2 (ja
JP2009504591A (ja
Filing date
Publication date
Priority claimed from GB0516464A external-priority patent/GB0516464D0/en
Priority claimed from GB0607736A external-priority patent/GB0607736D0/en
Priority claimed from GB0614569A external-priority patent/GB0614569D0/en
Application filed filed Critical
Priority claimed from PCT/EP2006/007865 external-priority patent/WO2007017261A1/en
Publication of JP2009504591A publication Critical patent/JP2009504591A/ja
Publication of JP2009504591A5 publication Critical patent/JP2009504591A5/ja
Application granted granted Critical
Publication of JP5112316B2 publication Critical patent/JP5112316B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008525474A 2005-08-10 2006-08-08 選択的hm74aアゴニストとしてのキサンチン誘導体 Expired - Fee Related JP5112316B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0516464A GB0516464D0 (en) 2005-08-10 2005-08-10 Novel compounds
GB0516464.5 2005-08-10
GB0607736A GB0607736D0 (en) 2006-04-19 2006-04-19 Novel compounds
GB0607736.6 2006-04-19
GB0614569A GB0614569D0 (en) 2006-07-21 2006-07-21 Novel compounds
GB0614569.2 2006-07-21
PCT/EP2006/007865 WO2007017261A1 (en) 2005-08-10 2006-08-08 Xanthine derivatives as selective hm74a agonists

Publications (3)

Publication Number Publication Date
JP2009504591A JP2009504591A (ja) 2009-02-05
JP2009504591A5 true JP2009504591A5 (enExample) 2012-10-11
JP5112316B2 JP5112316B2 (ja) 2013-01-09

Family

ID=37189397

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008525474A Expired - Fee Related JP5112316B2 (ja) 2005-08-10 2006-08-08 選択的hm74aアゴニストとしてのキサンチン誘導体
JP2008525475A Withdrawn JP2009504592A (ja) 2005-08-10 2006-08-08 選択的hm74aアゴニストとしてのキサンチン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008525475A Withdrawn JP2009504592A (ja) 2005-08-10 2006-08-08 選択的hm74aアゴニストとしてのキサンチン誘導体

Country Status (28)

Country Link
US (3) US20100179128A1 (enExample)
EP (3) EP1912992A1 (enExample)
JP (2) JP5112316B2 (enExample)
KR (2) KR20080034993A (enExample)
AR (1) AR055369A1 (enExample)
AT (1) ATE487719T1 (enExample)
AU (2) AU2006278216A1 (enExample)
BR (2) BRPI0615145A2 (enExample)
CA (2) CA2626723A1 (enExample)
CR (2) CR9749A (enExample)
CY (1) CY1111757T1 (enExample)
DE (1) DE602006018151D1 (enExample)
DK (1) DK1912991T3 (enExample)
EA (2) EA014556B1 (enExample)
ES (1) ES2401128T3 (enExample)
HR (1) HRP20100725T1 (enExample)
IL (2) IL189083A0 (enExample)
MA (2) MA29692B1 (enExample)
MX (2) MX2008001931A (enExample)
MY (1) MY142067A (enExample)
NO (2) NO20081211L (enExample)
NZ (1) NZ565494A (enExample)
PE (1) PE20070405A1 (enExample)
PL (1) PL1912991T3 (enExample)
PT (1) PT1912991E (enExample)
SI (1) SI1912991T1 (enExample)
TW (1) TW200800217A (enExample)
WO (2) WO2007017262A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
CN101863888B (zh) * 2004-02-14 2012-07-18 葛兰素史密斯克莱有限责任公司 具有hm74a受体活性的药物
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
EA014556B1 (ru) * 2005-08-10 2010-12-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные ксантина в качестве селективных агонистов hm74a
ATE486874T1 (de) 2006-06-23 2010-11-15 Incyte Corp Purinonderivate als hm74a-agonisten
AU2007260851B2 (en) 2006-06-23 2013-01-17 Incyte Corporation Purinone derivatives as HM74a agonists
MX2009001043A (es) 2006-08-08 2009-02-06 Sanofi Aventis Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
AU2009324811B2 (en) 2008-12-08 2013-01-24 Glaxosmithkline Llc Novel compounds
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR101799429B1 (ko) * 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
BR112013003439A2 (pt) * 2010-08-16 2019-09-24 Boehringer Ingelheim Int "inibidores de oxadiazol de produção de leucotrieno"
EP2619196B1 (en) * 2010-09-23 2015-09-16 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2868240A1 (en) * 2012-05-30 2013-12-05 F. Hoffmann-La Roche Ag Triazolo compounds as pde10 inhibitors
PE20151779A1 (es) * 2013-03-15 2015-11-20 Hydra Biosciences Inc Xantinas sustituidas y metodos de uso de las mismas
EP2994141A4 (en) 2013-05-10 2016-11-23 Nimbus Apollo Inc ACC-HEMMER AND USES THEREOF
CN105358152A (zh) * 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
HK1221661A1 (zh) 2013-05-10 2017-06-09 Gilead Apollo, Llc Acc抑制剂和其用途
EA030958B1 (ru) 2013-05-10 2018-10-31 Джилид Аполло, Ллс Ингибиторы акк и их применение
CN105646492B (zh) * 2014-11-14 2019-04-09 中国医学科学院药物研究所 含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途
DE102017000359A1 (de) 2016-08-26 2018-03-01 Bihl+Wiedemann Gmbh Diagnose-Repeater für AS-Interface Netze
JP7178357B2 (ja) * 2017-03-07 2022-11-25 エフ.ホフマン-ラ ロシュ アーゲー オキサジアゾール一過性受容器電位チャネル阻害剤
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用
MX2024009581A (es) * 2022-02-03 2024-08-13 De Shaw Res Llc Compuestos de uracilo n3-sustituidos como inhibidores de trpa1.
TW202440084A (zh) * 2023-01-30 2024-10-16 美商D E 蕭爾研究有限公司 作為trpa1抑制劑之雙環醯亞胺化合物
AR133217A1 (es) * 2023-07-10 2025-09-10 De Shaw Res Llc Inhibidores de trpa1 bicíclicos y monocíclicos

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
AU3725893A (en) 1992-02-21 1993-09-13 Smithkline Beecham Corporation TNF inhibitors
ATE230990T1 (de) 1992-03-04 2003-02-15 Cell Therapeutics Inc Enantiomere hydroxylierte xanthinverbindungen
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US5780476A (en) 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
WO1994024133A1 (en) 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
CA2183562A1 (en) 1994-02-18 1995-08-24 J. Peter Klein Intracellular signalling mediators
US6878715B1 (en) 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US6780865B1 (en) 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
US6103730A (en) 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
EP1171442B1 (en) 1999-04-09 2005-12-07 Cell Therapeutics, Inc. Xanthine derivatives and analogs as cell signalling inhibitors
US20030207901A1 (en) 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6586429B2 (en) * 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
HU230382B1 (hu) 2001-02-24 2016-03-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként
AU2002242910A1 (en) 2001-04-11 2002-10-28 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
ATE388951T1 (de) * 2001-07-03 2008-03-15 Novo Nordisk As Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
DE60304911D1 (de) 2002-02-25 2006-06-08 Eisai Co Ltd Xanthin-Derivate als DPP-IV-Inhibitoren
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
CN1227492C (zh) * 2003-03-11 2005-11-16 张跃 一种吸收式空调主体
GB0319124D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
CN101863888B (zh) * 2004-02-14 2012-07-18 葛兰素史密斯克莱有限责任公司 具有hm74a受体活性的药物
KR20070070231A (ko) * 2004-10-22 2007-07-03 스미스클라인 비참 코포레이션 Hm74a 수용체 활성을 가지는 크산틴 유도체
WO2006045564A1 (en) * 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
US20090209561A1 (en) * 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
JP2008530074A (ja) 2005-02-14 2008-08-07 スミスクライン・ビーチャム・コーポレイション Hm74a受容体アゴニストとしてのアントラニル酸誘導体
GB0516462D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
EA014556B1 (ru) * 2005-08-10 2010-12-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные ксантина в качестве селективных агонистов hm74a
DE102008009758A1 (de) * 2008-02-18 2009-08-20 Beiersdorf Ag Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on zur verbesserten Hautkonturierung bzw. gegen Cellulite
AU2009324811B2 (en) 2008-12-08 2013-01-24 Glaxosmithkline Llc Novel compounds

Similar Documents

Publication Publication Date Title
JP2009504591A5 (enExample)
JP2006520397A5 (enExample)
JP2008510828A5 (enExample)
JP2008523069A5 (enExample)
JP2020502049A5 (enExample)
JP2015535832A5 (enExample)
JP2007503405A5 (enExample)
JP2007503487A5 (enExample)
JP2019104748A5 (enExample)
JP2017507160A5 (enExample)
JP2006514691A5 (enExample)
JP2008500997A5 (enExample)
JP2005523922A5 (enExample)
JP2007534702A5 (enExample)
JP2009515988A5 (enExample)
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
JP2009511490A5 (enExample)
JP2012526728A5 (enExample)
JP2018529650A5 (enExample)
JP2008505194A5 (enExample)
JP2019532092A5 (enExample)
JP2013502441A5 (enExample)
JP2006507355A5 (enExample)
JP2010520851A5 (enExample)
JP2010520214A5 (enExample)